Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Amy V. Kapp"'
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Autor:
Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura
Publikováno v:
Cancer Research. 80:OT1-08
Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanis
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Marcos Vinicius Silva Oliveira, Amy V. Kapp, Wai Y. Chan, Steven Gendreau, Stina M. Singel, S-B Kim, Matthew Wongchenko, Rebecca Dent, Cristina Saura, Daniel J. Maslyar, J. Baselga
Publikováno v:
Cancer Research. 78:P2-09
Background: The oral Akt inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/Akt pathway activation. In the placebo-controlled randomized phase II LOTUS trial (NCT02162719), adding IPAT to PAC as first-line therapy for metasta
Autor:
Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall
Publikováno v:
Cancer. 122:3803-3811
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Autor:
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga, Keun Seok Lee, Hwei-Chung Wang, Antoinette Tan, Joo Hyuk Sohn, Michelino De Laurentiis, Laura Garcia Estevez, Chiun-Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva, Pier Franco Conte, Shaker Dakhil, Marc Debled, Antonio Gonzalez Martin, Sara Hurvitz, Jee Hyun Kim, Christelle Levy, Pedro Sanchez Rovira, Jae Hong Seo, Vicente Valero, Gregory Vidal, Andrea Wong, Mary Ann K Allison, Robert Figlin, David Chan, Shin-Cheh Chen, Yen-Hsun Chen, Melody Cobleigh, Filippo De Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven Isakoff, William Lawler, Alvaro Montaño, Mohamad Salkini, Leonard Seigel
Publikováno v:
The Lancet. Oncology, vol 18, iss 10
Summary Background The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23bb66843d8ecfd467caeec1baf17b8a
https://escholarship.org/uc/item/7z70q2hf
https://escholarship.org/uc/item/7z70q2hf
Autor:
Maria Anderson, Danny Rischin, William D. Hanley, Jérôme Fayette, Andrea Pirzkall, Dana Cernea, Tibor Csoszi, Amy V. Kapp, Cristina Oprean, Christopher M. Nutting, Paul M. Harari, Lori J. Wirth, Bruce McCall, Paul H. O'Brien, Anghel Udrea, Elicia Penuel, Jan B. Vermorken, Antonio Jimeno
Publikováno v:
Frontiers in Oncology
Frontiers in oncology
Frontiers in Oncology, Vol 6 (2016)
Frontiers in oncology
Frontiers in Oncology, Vol 6 (2016)
Background: Duligotuzumab, a novel dual -action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers
Autor:
Rebecca Dent, Matthew Wongchenko, Cristina Saura, Wai Y. Chan, Daniel J. Maslyar, Amy V. Kapp, Mafalda Oliveira, Stina M. Singel, J. Baselga, S-B Kim, Steven Gendreau
Publikováno v:
Annals of Oncology. 28:v33-v34
Autor:
Begoña Bermejo, Isabel Calvo, Miguel Gil, José Baselga, José Luis Passos Coelho, Debra A. Patt, Eva Ciruelos, Amy V. Kapp, Daniel J. Maslyar, Wai Y. Chan, Mafalda Oliveira, Lorena de la Peña, Stina M. Singel, Cristina Saura, Steven J. Isakoff, Jay Andersen, Matthew Wongchenko
Publikováno v:
Cancer Research. 78:CT041-CT041
Purpose: This hypothesis-generating trial evaluated neoadjuvant IPAT + PAC for eTNBC. Methods: Patients (pts) with eTNBC, T ≥1.5 cm and N0-2 were randomized 1:1 to receive 12 wks of weekly PAC 80 mg/m² + either IPAT 400 mg or PBO d1-21 q28d before
Autor:
Rebecca Dent, Doron Lipson, Cristina Saura, José Baselga, Wai Y. Chan, Virginia Breese, Alyssa Tsiros, Mark Kennedy, Sung Bae Kim, Amy V. Kapp, Matthew Wongchenko, Mandy Greene, Stina M. Singel, Travis A. Clark, Mafalda Oliveira, Steven Gendreau
Publikováno v:
Cancer Research. 78:2964-2964
Purpose: There is high interest in longitudinal analysis of plasma ctDNA as an early predictor of response and long-term outcomes. We report a retrospective longitudinal analysis of ctDNA in the double-blind placebo (PBO)-controlled randomized phase